Medical paternalism and expensive unsubsidised drugs

doi:10.1136/bmj.331.7524.1075

BMJ 2005;331:1075-1077 (5 November), doi:10.1136/bmj.331.7524.1075

Education and debate

Medical paternalism and expensive unsubsidised drugs

Michael Jefford, medical oncologist¹, Julian Savulescu, ethicist², Jacqui Thomson, medical oncologist¹, Penelope Schofield, behavioural scientist¹, Linda Mileshkin, medical oncologist¹, Emilia Agalianos, research assistant¹, John Zalcberg, medical oncologist¹

¹ Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Locked Bag 1, A'Beckett Street, Victoria 8006, Australia, ² Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford

Correspondence to: M Jefford Michael.Jefford@petermac.org

When discussing treatment with patients, doctors may not mentionnewly licensed drugs that are not yet funded by healthcare schemes.Although their motives are good, the ethics are questionable

The first 150 words of the full text of this article appear below.

Introduction

The development of new drugs can be a lengthy process, requiringinitial laboratory and animal testing and then a course of clinicalstudies.¹ Clinical assessment involves phase I testing, whichfocuses on determination of side effects and an appropriatedose for later study; phase II studies, which assess efficacyin people with a particular condition; and phase III studies,which generally compare a new, experimental treatment with anexisting standard treatment. Once a therapeutic benefit hasbeen shown, the drug company can apply for approval from therelevant regulatory body. An extensive review follows, whichmay take many months or years. If the drug is approved, furtherdelays may occur before funding arrangements permit the drugto be widely available. We consider some of the ethical dilemmassurrounding this process, using the example of drugs to treatpeople with cancer.

Unsubsidised, expensive drugs

In Australia, the cost of most prescription medicines is subsidised. . . [Full text of this article]

Practice of discussing unfunded drugs

Ethics of discussing unfunded drugs

Access to drugs in development

Cost of new drugs

Conclusions

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

Technorati What's this?

A comprehensive service: Tony Delamothe
BMJ 2008 336: 1344-1345. [Extract] [Full Text] [PDF]

Paternalism can stand in the way of best treatment
BMJ 2005 331: 0. [Full Text]

Survival of the richest: Fiona Godlee
BMJ 2005 331: 0. [Extract] [Full Text] [PDF]

How the internet affects patients' experience of cancer: a qualitative study: Sue Ziebland, Alison Chapple, Carol Dumelow, Julie Evans, Suman Prinjha, and Linda Rozmovits
BMJ 2004 328: 564. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

Delamothe, T. (2008). A comprehensive service. BMJ 336: 1344-1345 [Full text]
Donnelly, P, Hiller, L, Bathers, S, Bowden, S, Coleman, R (2007). Questioning specialists' attitudes to breast cancer follow-up in primary care. Ann Oncol 18: 1467-1476 [Abstract] [Full text]
Thomson, J., Schofield, P., Mileshkin, L., Agalianos, E., Savulescu, J., Zalcberg, J., Jefford, M. (2006). Do oncologists discuss expensive anti-cancer drugs with their patients?. Ann Oncol 17: 702-708 [Abstract] [Full text]

Rapid Responses:

Read all Rapid Responses

Test of ethics: J.David Leopold
bmj.com, 7 Nov 2005 [Full text]
Market Altruism: Andrew J Ashworth
bmj.com, 7 Nov 2005 [Full text]
Re: Test of ethics: Rosetta Manaszewicz
bmj.com, 7 Nov 2005 [Full text]
How can we turn cancer into a chronic disease that we can afford to treat?: Michael P. Brown, et al.
bmj.com, 2 Feb 2006 [Full text]